| Literature DB >> 26440050 |
Lei Zhou1,2,3, Pengfei Cui1,4, Shengqiang Zhao1,5, Taiyang Ye1,6, Yan Li1,5, Jin Peng1,7, Gengming Niu1,8, Dezheng Zhao1,9, Huiyan Zeng10,11.
Abstract
TR3 has been reported to be an excellent target for angiogenesis therapies. We reported three TR3 transcript variant messenger RNAs (mRNAs) are expressed in human umbilical vein endothelial cell (HUVEC) and are differentially regulated by vascular endothelial growth factor (VEGF). TR3 transcript variant 1 (TR3-TV1) and variant 2 (TR3-TV2) encoding the same TR3 isoform 1 protein (TR3-iso1) that was named TR3 has been extensively studied. However, the function of TR3 isoform 2 protein (TR3-iso2) encoded by TR3 transcript variant 3 (TR3-TV3) is still not known. Here, we clone and express the novel TR3-iso2 protein and find that expression of TR3-iso2, in contrast to TR3-iso1, inhibits endothelial cell proliferation induced by VEGF-A, histamine, and phorbol-12-myristate-13-acetate (PMA). The differential function of TR3-iso2 correlates with the down-regulation of cyclin D1. However, TR3-iso2 plays similar roles in endothelial cell migration and monolayer permeability as TR3-iso1. We further demonstrate that several intracellular signaling pathways are involved in histamine-induced TR3 transcript variants, including histamine receptor H1-mediated phospholipase C (PLC)/calcium /calcineurin/protein kinase C (PKC)/protein kinase D (PKD) pathway and ERK pathway, as well as histamine receptor H3-mediated PKC-ERK pathway. Further, expressions of TR3-TV1, TR3-TV2, and TR3-TV3 by VEGF and histamine are regulated by different promoters, but not by their mRNA stability.Entities:
Keywords: Angiogenesis; Cell proliferation; Cell signaling; Migration; TR3/Nur77 transcription variants
Mesh:
Substances:
Year: 2015 PMID: 26440050 PMCID: PMC4837113 DOI: 10.1007/s13277-015-4157-9
Source DB: PubMed Journal: Tumour Biol ISSN: 1010-4283